FDA lifts clinical hold on Arbutus Biopharma's AB-101 drug candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to FDA lifts clinical hold on Arbutus Biopharma's AB-101 drug candidate

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

October 22, 2026 7:30 AM EDT

WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (Arbutus or the Company), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the U.S. Food and Drug Administration (FDA) that the clinical hold on the Investigational New Drug (IND) application for AB-101 has been removed and that the Company may engage in additional clinical development for AB-101 in the United States. Arbutus is evaluating next steps for the continued development of AB-101.

AB-101 is a proprietary oral PD-L1 inhibitor that has the... More